<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418574</url>
  </required_header>
  <id_info>
    <org_study_id>ABA-01</org_study_id>
    <secondary_id>AGO-OVAR 10</secondary_id>
    <secondary_id>2006-002801-30</secondary_id>
    <nct_id>NCT00418574</nct_id>
  </id_info>
  <brief_title>Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients</brief_title>
  <acronym>MIMOSA</acronym>
  <official_title>A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an
      experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms
      of time the remission status is kept as well as prolongation of life expectancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard initial treatment of ovarian cancer patients includes both surgery and chemotherapy
      which in the vast majority of cases achieves the disappearance of ovarian cancer lesions.
      This status, called &quot;clinical remission&quot; which means having no evidence of cancer on CT scan
      or physical examination needs to be carefully follow up in order to confirm the maintenance
      of the remission status or to early detect if the cancer grows again and then start a new
      chemotherapy. At present, no approved therapies exist for the maintenance treatment of
      patients who achieved the clinical remission.

      This trial aims to evaluate if the repeated vaccination with Abagovomab creates an
      immunoresponse which is able to fight the cancer cells thus keeping the remission status as
      long as possible and help patients live disease-free and longer.

      Patients who achieve the remission status after chemotherapy will be screened for study
      participation and if they meet the criteria for inclusion they will start to receive a single
      subcutaneous injection every 2 weeks (for the first 4 doses - induction phase) and then every
      4 weeks (maintenance phase). The duration of treatment is up to approximately 4 years or it
      will be stopped in case relapse occurs.

      In order to evaluate the real benefit of vaccination, the experimental treatment includes
      Abagovomab (the active drug) or placebo (the vehicle only, without drug), with a double
      chance to receive Abagovomab. Assignment of Abagovomab or placebo will be done by a
      computerised system and nobody in the study will know which treatment has been allocated
      until study end.

      Patients will be visited every 4 weeks and will undergo CT scan of pelvis and abdomen every
      12 weeks in order to confirm the remission status or to early detect if relapse eventually
      occurs. This will be done in blind condition (i.e. without being aware which treatment the
      patient is going to receive) for the first part of the study which is expected to last four
      years. After then the overall status of patient will continue to be monitored by phone
      contact for additional five years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No benefit on primary end point (RFS); no rationale to collect survival data
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)</measure>
    <time_frame>Every 12 weeks up to recurrence or up to 3 months after last administered dose</time_frame>
    <description>The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>2 years survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Along treatment administration and up to double blind observation period. i.e. for each patient after the first dose administration till the f inal study visit, or within 12 weeks of the last dose</time_frame>
    <description>Safety was analyzed in all patients who received at least 1 dose administration.
Adverse event (AE) are defined as events which started on or after the first dose of study medication and on or before the date of the final study visit, or within 12 weeks of the last dose if the final study visit was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Immunoresponse</measure>
    <time_frame>at baseline, at week 10 after first dose administration and at final study visit (at week 4 or week 12 after the last administered dose, as appropriate)</time_frame>
    <description>Time course of immunologic parameters (anti-anti-idiotypic antibody - Ab3) will be assessed in all patients, by comparing levels at baseline (week 0), at week 10 after first dose administration and at end of treatment (at week 4 or week 12 after the last administered dose, as appropriate).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">888</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Abagovomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Abagovomab</intervention_name>
    <description>2 mg/ml SC (subcutaneously)</description>
    <arm_group_label>Abagovomab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mg/ml SC (subcutaneously)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At a maximum of 12 weeks after the last cycle of first line standard platinum/taxane
        intravenous (IV) or intraperitoneal (IP) chemotherapy, patients must fulfill all the
        following inclusion criteria:

          -  Age &gt;/= 18 years;

          -  Properly executed written informed consent;

          -  History of histological and CA125 (&gt; 35 U/ml) confirmed diagnosis of stage III-IV
             epithelial ovarian, fallopian tube, or primary peritoneal cancer;

          -  History of debulking surgery and 6-8 cycles of standard platinum/taxane based
             non-investigational IV-IP chemotherapy;

          -  Complete clinical response defined as:

          -  Normal physical examination;

          -  No symptoms suggestive of persistent cancer;

          -  No definite evidence of disease by computed tomography (CT) of the abdomen and pelvis
             within the previous 4 weeks;

          -  Negative chest x-ray (or chest CT scan) within the previous 4 weeks;

          -  Serum CA125 within the normal laboratory range.

          -  Adequate hematologic, renal and hepatic function:

               -  Absolute Neutrophil Count (ANC) &gt;/=1.5 * 109/l;

               -  Platelets &gt;/= 75 * 109/l;

               -  Haemoglobin &gt;/= 6.2 mmol/l (&gt;9.9 g/dl);

               -  Serum creatinine &lt;/= 1.5 * ULN (Upper Limit of Normal);

               -  Bilirubin &lt;/= 1.5 * ULN; AST, ALT, AP &lt;/= 2.5 * ULN.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) &lt;/= 2.

        Exclusion Criteria:

        Patients are ineligible to participate in the study, if any of the following criteria are
        present:

          -  any other invasive malignancies, with the exception of non-melanoma skin cancer or
             cervical carcinoma in situ, within the last 5 years or whose previous cancer treatment
             contraindicates this protocol therapy;

          -  known active autoimmune disease requiring chronic treatment with immunosuppressive
             agents (e.g., rheumatoid arthritis, ulcerative colitis, etc.);

          -  known immune deficiency (e.g. HIV, hypogammaglobulinemia, etc.);

          -  known infection with hepatitis B, or hepatitis C;

          -  history of recent myocardial infarction (&lt;/= 6 months) or decompensated heart failure
             (New York Heart Association - NYHA class &gt;/= III);

          -  previous or concomitant use of any anti-cancer therapy other than the platinum-taxane
             based 1st line chemotherapy for ovarian cancer; any maintenance or consolidation
             therapy is not permitted after completion of standard front line chemotherapy.

          -  concomitant use of any other investigational agent;

          -  any prior investigational anti-cancer vaccine or monoclonal antibody;

          -  known allergy to murine proteins;

          -  any significant medical or psychiatric condition, drug or alcohol abuse that might
             prevent the patient from complying with all study procedures;

          -  clinically significant active infection;

          -  concomitant use of any immunosuppressive agent (e.g., steroids, cyclosporin, etc.);

          -  major surgery within the previous 2 weeks;

          -  radiotherapy within the previous 4 weeks;

          -  any significant toxicity from prior chemotherapy;

          -  unreliability or inability to follow protocol requirements;

          -  potentially childbearing and not willing to use adequate contraceptive methods
             throughout the entire study period;

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobus Pfisterer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AGO-OVAR, Ovarian Cancer Study Group, Germany; Ubbo-Emmius-Klinik gGmbH Aurich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Centre- NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Berek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COGI (Cooperative Ovarian Cancer Group for Immunotherapy); Dept Obstetrics and Gynecology, Stanford CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Scambia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtita' Cattolica del Sacro Cuore, Dipartimento di Oncologia - Roma, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Casado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico San Carlos, Servicio de Oncología Medica - Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Pluzanska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Chemioterapii Nowotworów Akademii Medycznej w Łodzi, Regionalny Osrodek Onkologiczny - Lodz, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karel Cwiertka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onkologická klinika Fakultni Nemocnice Olomouc, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamás Pintér, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Petz Aladar Megyei Oktató Kórház, Onkoradiológia - Győr, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Pujade-Lauraine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Hotel Dieu - Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curtis and Elizabeth Anderson Cancer Institute</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Pavilion</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harry and Jeanette Weinberg Cancer Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Care Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center, Obstetrics and Gynecology Oncology</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Centre</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Stedelijk Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent Medische Oncologie 4B-Z</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liége (Sart Tilman)</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elizabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Augustinus, Oncologisch Centrum GVA</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>65677</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOU Zluty Kopec</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Ceske Budejovice, a.s.</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37087</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec, oddeleni gynekologicko porodnicke</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice</name>
      <address>
        <city>Pardubice</city>
        <zip>53203</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynekologicko-porodnicka klinika FN Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>32600</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice</name>
      <address>
        <city>Praha 2</city>
        <zip>12851</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Bulovka</name>
      <address>
        <city>Praha 8</city>
        <zip>18000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice T. Bati</name>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans Cedex</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes Cedex</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken GmbH, Klinikum Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09009</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Josefs-Hospital Cloppenburg</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreisklinik Ebersberg gGmbH</name>
      <address>
        <city>Ebersberg</city>
        <zip>85560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der JWG Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60591</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ernst-Moritz-Universität</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg, Klinikum der Medizinischen Fakultät</name>
      <address>
        <city>Halle/Saale</city>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskrankenhaus Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken AG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>32125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Leonberg</name>
      <address>
        <city>Leonberg</city>
        <zip>71229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Lich</name>
      <address>
        <city>Lich</city>
        <zip>35423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincenz-Krankenhaus</name>
      <address>
        <city>Limburg</city>
        <zip>65549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik St. Marienstift</name>
      <address>
        <city>Magdeburg</city>
        <zip>39101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen u. Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Innenstadt</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Offenbach GmbH</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz-Krankenhaus Paderborn</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elblandkliniken Meißen-Radebeul GmbH</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Südstadt der Hansestadt Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>r. Horst Schmidt Kliniken GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Wolfsburg-FrauenklinikWolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fővárosi Önkormányzat Szent Margit Kórháza, Onkológia</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. sz. Szülészeti és Nőgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem, I sz. Szülészeti és Nőgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos és Egészségtudományi Centrum, Szülészetl es Nőgyógyászatl Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktató Kórház, Onkoradiológia</name>
      <address>
        <city>Győr</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Kórháza, Szülészet-Nőgyógyászati Osztály</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem, ÁOK Szülészeti és Nőgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komárom-Esztergom Megyei Onkormanyzat Szent Borbála Kórház, Szülészet-Nőgyógyászati Osztály</name>
      <address>
        <city>Tatabanya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ginecologia e Ostetricia 2^, Università degli studi di Bari, Policlinico</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Orsola Malpighi, Oncologia Medica</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtita' Cattolica del Sacro Cuore Dipartimento di Oncologia</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DH Oncologico U.O. Medicina Oncologica Ospedale Ramazzini</name>
      <address>
        <city>Carpi (MO)</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Ospedale di Faenza - AUSL di Ravenna</name>
      <address>
        <city>Faenza</city>
        <zip>48018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Martino - Padiglione Malattie Complesse, Dipartimento di Oncologia Medica</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia - Divisione di Ginecologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena, Dipartimento di Oncologia ed Ematologia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo studio e la cura dei tumori &quot;Fondazione Pascale&quot; Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Carlo - Oncologia Medica</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Bianchi-Melacrino-Morelli - Oncologia Medica</name>
      <address>
        <city>Reggio di Calabria</city>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova, Oncologia Medica</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I D.H. Oncologico Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ginecologia ed Ostetricia Policlinico Universitario Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza - Unita' Operativa di Ostetricia e Ginecologia</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Discipline Ginecologiche e Ostetriche - Universita degli Studi di Torino - Azienda ospedaliera O.I.R.M.-S'Anna</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny Nr 4</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Onkologii Wojewódzki Szpital Specjalistyczny</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Gdansk</city>
        <zip>80-210</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vesalius Kraków</name>
      <address>
        <city>Krakow</city>
        <zip>31-108</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Centrum Onkologii, Instytut im. M. Skłodowskiej-Curie, Oddział w Krakowie,</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chemioterapii Nowotworów Akademii Medycznej w Łodzi, Regionalny Osrodek Onkologiczny</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chemioterapii ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii, Oddzial Chemioterapii Akademii Medycznej w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Wojewodzki Szpital Specjalistyczny Nr 3, Oddzial Onkologii</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony, Oddzial Onkologii Klinicznej</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny; Klinika Onkologii Centralnego Szpitala Klinicznego MON</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA, Klinika Onkologii, Hematologii i Chorob Wewnetrznych</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Klinika Nowotworów Narządów Płciowych Kobiecych</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias y Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón, Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona, Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Elche, Servico de Oncologia</name>
      <address>
        <city>Elche</city>
        <zip>3203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología - Hospital Universitari de Girona &quot;Dr. Josep Trueta&quot;. Oncologia Medica</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez de Huelva</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico Regional de Galicia, Servicio de Oncologia Medica</name>
      <address>
        <city>La Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova, Servicio de Oncologia</name>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Internacional Espana</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos, Servicio de Oncología Medica</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Malaga. Servicio de Oncologia</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta, Servicio de Oncología</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>7014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res. 2004 Mar 1;10(5):1580-7.</citation>
    <PMID>15014007</PMID>
  </reference>
  <reference>
    <citation>Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Möbus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clin Cancer Res. 2001 May;7(5):1154-62.</citation>
    <PMID>11350879</PMID>
  </reference>
  <reference>
    <citation>Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006 Oct;17(10):1568-77.</citation>
    <PMID>17005631</PMID>
  </reference>
  <reference>
    <citation>Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 2006 Sep 15;12(18):5503-10.</citation>
    <PMID>17000686</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <results_first_submitted>July 1, 2011</results_first_submitted>
  <results_first_submitted_qc>October 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2011</results_first_posted>
  <last_update_submitted>November 17, 2011</last_update_submitted>
  <last_update_submitted_qc>November 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Abagovomab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study population was recruited in 139 sites (Hospitals/University Clinics) distributed in Europe (Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland and Spain) and US.
Date of first patient randomised: 08 December 2006 Date of last patient randomised: 26 December 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Abagovomab</title>
          <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="593"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="592"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="545"/>
                <participants group_id="P2" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Abagovomab</title>
          <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="593"/>
            <count group_id="B2" value="295"/>
            <count group_id="B3" value="888"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="10.57"/>
                    <measurement group_id="B2" value="56.0" spread="10.47"/>
                    <measurement group_id="B3" value="56.3" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="593"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology of ovarian tumor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serous/papillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometrioid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucinous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undifferentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status (ECOG-PS)</title>
          <description>This scale and criteria are used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. The scale runs from the score 0 to 5, with 0 denoting the status &quot;Fully active, able to carry on all pre-disease performance without restriction&quot; and 5 the status &quot;Dead&quot;.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="460"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Grade of histologic differentiation</title>
          <description>Histologic grade, also called differentiation, refers to how much the tumor cells resemble normal cells of the same tissue type.
GX Grade cannot be assessed (Undetermined grade) G1 Well-differentiated (Low grade) - best prognosis G2 Moderately differentiated (Intermediate grade) G3 Poorly differentiated (High grade) G4 Undifferentiated (High grade) - worst prognosis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>G1-G2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3-G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Federation of Gynecology and Obstetrics (FIGO) stage</title>
          <description>International system of staging which identifies the spread of the ovarian cancer at the point of diagnosis [STAGE 1 - Tumour is confined to the ovary / ovaries; STAGE 2 – Tumour involves one or both ovaries and has extended into the pelvis; STAGE 3 – The tumour involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis, includes liver capsule metastasis; STAGE: 4 – Distant metastasis beyond the peritoneal cavity, liver parenchymal metastasis.]</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="513"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor size after debulking surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 1 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="479"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 1 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum CA-125 after 3rd chemotherapy cycle</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 35 U/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="479"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 35 U/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)</title>
        <description>The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan.</description>
        <time_frame>Every 12 weeks up to recurrence or up to 3 months after last administered dose</time_frame>
        <population>intention to treat (ITT) population (i.e. all randomized patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Abagovomab</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)</title>
          <description>The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan.</description>
          <population>intention to treat (ITT) population (i.e. all randomized patients)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="593"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403" lower_limit="323" upper_limit="414"/>
                    <measurement group_id="O2" value="402" lower_limit="323" upper_limit="487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.301</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.919</ci_lower_limit>
            <ci_upper_limit>1.315</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>2 years survival rate</description>
        <time_frame>2 years</time_frame>
        <population>intention to treat (ITT) population (i.e. all randomized patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Abagovomab</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>2 years survival rate</description>
          <population>intention to treat (ITT) population (i.e. all randomized patients)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="593"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Safety was analyzed in all patients who received at least 1 dose administration.
Adverse event (AE) are defined as events which started on or after the first dose of study medication and on or before the date of the final study visit, or within 12 weeks of the last dose if the final study visit was not performed.</description>
        <time_frame>Along treatment administration and up to double blind observation period. i.e. for each patient after the first dose administration till the f inal study visit, or within 12 weeks of the last dose</time_frame>
        <population>Safety population (i.e. All randomized patients who received at least one dose treatment administration)</population>
        <group_list>
          <group group_id="O1">
            <title>Abagovomab</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Safety was analyzed in all patients who received at least 1 dose administration.
Adverse event (AE) are defined as events which started on or after the first dose of study medication and on or before the date of the final study visit, or within 12 weeks of the last dose if the final study visit was not performed.</description>
          <population>Safety population (i.e. All randomized patients who received at least one dose treatment administration)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with at least 1 Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564"/>
                    <measurement group_id="O2" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with at least 1 Adverse Drug Reaction ADR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with at least 1 Serious Adverse Event SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with at least 1 Serious ADR (SADR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with at least 1 AE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with at least 1 AE resulted in death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Immunoresponse</title>
        <description>Time course of immunologic parameters (anti-anti-idiotypic antibody - Ab3) will be assessed in all patients, by comparing levels at baseline (week 0), at week 10 after first dose administration and at end of treatment (at week 4 or week 12 after the last administered dose, as appropriate).</description>
        <time_frame>at baseline, at week 10 after first dose administration and at final study visit (at week 4 or week 12 after the last administered dose, as appropriate)</time_frame>
        <population>Participants who received abagovomab (evaluable population)and have baseline serum sample: 576 at baseline; 538 at week 10 after first dose intake; 449 at the final study visit</population>
        <group_list>
          <group group_id="O1">
            <title>Abagovomab</title>
            <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of Immunoresponse</title>
          <description>Time course of immunologic parameters (anti-anti-idiotypic antibody - Ab3) will be assessed in all patients, by comparing levels at baseline (week 0), at week 10 after first dose administration and at end of treatment (at week 4 or week 12 after the last administered dose, as appropriate).</description>
          <population>Participants who received abagovomab (evaluable population)and have baseline serum sample: 576 at baseline; 538 at week 10 after first dose intake; 449 at the final study visit</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="576"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ab3 (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="118000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab3 (week 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63550" lower_limit="0" upper_limit="777000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ab3 (end of treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493000" lower_limit="0" upper_limit="2720000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <desc>Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)</desc>
      <group_list>
        <group group_id="E1">
          <title>Abagovomab</title>
          <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="592"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Lymphatic system disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Thrombocytopenias</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic coronary artery disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pericardial disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorders (excl infections)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Thyroid hyperfunction disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucomas (excl congenital)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Retinal structural change, deposit and degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal findings abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Abdominal hernias, site unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Acute and chronic pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Diarrhoea (excl infective)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Duodenal and small intestinal stenosis and obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Dyspeptic signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastric and oesophageal haemorrhages</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastritis (excl infective)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal and abdominal pains (excl oral and throat)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="592"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal atonic and hypomotility disorders NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammatory disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis and gangrene (excl gangrenous hernia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stenosis and obstruction NEC</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="592"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis and obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting symptoms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Non-site specific gastrointestinal haemorrhages</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Peritoneal and retroperitoneal disorders</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="592"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Peritoneal and retroperitoneal fibrosis and adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device issues NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Febrile disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>General signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Hernias NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Injection site reactions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Oedema NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Therapeutic and nontherapeutic responses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis and cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Cholestasis and jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gallbladder disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic conditions NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal and gastrointestinal infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Aspergillus infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Bacterial infections NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Dental and oral soft tissue infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Ear infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Herpes viral infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Influenza viral infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Sepsis, bacteraemia, viraemia and fungaemia NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Streptococcal infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Vascular infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injuries NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Lower limb fractures and dislocations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Non-site specific injuries NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pelvic fractures and dislocations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Spinal fractures and dislocations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Upper limb fractures and dislocations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Digestive enzymes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Liver function analyses</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Renal function analyses</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Skeletal and cardiac muscle analyses</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Tissue enzyme analyses NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus (incl subtypes)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone related signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Joint related signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Metabolic bone disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue pain and discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Osteoarthropathies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Soft tissue disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Spine and neck deformities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bone neoplasms benign (excl cysts)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Endocrine neoplasms malignant and unspecified NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasms malignant NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Metastases to specified sites</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="592"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Neoplasms malignant site unspecified NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Neoplasms unspecified malignancy and site unspecified NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Nervous system neoplasms unspecified malignancy NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Non-small cell neoplasms malignant of the respiratory tract cell type specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Oncologic complications and emergencies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasms malignant (excl germ cell)</sub_title>
                <counts group_id="E1" events="80" subjects_affected="61" subjects_at_risk="592"/>
                <counts group_id="E2" events="46" subjects_affected="41" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Rectal neoplasms malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Skin neoplasms malignant and unspecified (excl melanoma)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Vaginal neoplasms malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system haemorrhages and cerebrovascular accidents</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Disturbances in consciousness NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathies NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Seizures and seizure disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Speech and language abnormalities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Transient cerebrovascular events</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Depressive disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure and impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Renal obstructive disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Ureteric disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Uterine disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing abnormalities</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pneumothorax and pleural effusions NEC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="592"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombotic and embolic conditions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Connective tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Dermal and epidermal conditions NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Dermatitis and eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated and malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Aortic embolism and thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Lymphangiopathies</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Lymphoedemas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Non-site specific embolism and thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Peripheral embolism and thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="532" subjects_at_risk="592"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea (excl infective)</sub_title>
                <counts group_id="E1" events="177" subjects_affected="98" subjects_at_risk="592"/>
                <counts group_id="E2" events="64" subjects_affected="41" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Flatulence, bloating and distension</sub_title>
                <counts group_id="E1" events="69" subjects_affected="45" subjects_at_risk="592"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal and abdominal pains (excl oral and throat)</sub_title>
                <counts group_id="E1" events="300" subjects_affected="183" subjects_at_risk="592"/>
                <counts group_id="E2" events="125" subjects_affected="81" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Gastrointestinal atonic and hypomotility disorders NEC</sub_title>
                <counts group_id="E1" events="115" subjects_affected="82" subjects_at_risk="592"/>
                <counts group_id="E2" events="54" subjects_affected="38" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting symptoms</sub_title>
                <counts group_id="E1" events="325" subjects_affected="130" subjects_at_risk="592"/>
                <counts group_id="E2" events="138" subjects_affected="64" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenic conditions</sub_title>
                <counts group_id="E1" events="431" subjects_affected="191" subjects_at_risk="592"/>
                <counts group_id="E2" events="240" subjects_affected="89" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Febrile disorders</sub_title>
                <counts group_id="E1" events="111" subjects_affected="67" subjects_at_risk="592"/>
                <counts group_id="E2" events="73" subjects_affected="40" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Feelings and sensations NEC</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="592"/>
                <counts group_id="E2" events="25" subjects_affected="14" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>General signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="75" subjects_affected="44" subjects_at_risk="592"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Injection site reactions</sub_title>
                <counts group_id="E1" events="4906" subjects_affected="467" subjects_at_risk="592"/>
                <counts group_id="E2" events="2352" subjects_affected="222" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Oedema NEC</sub_title>
                <counts group_id="E1" events="82" subjects_affected="61" subjects_at_risk="592"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="592"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" events="49" subjects_affected="43" subjects_at_risk="592"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" events="242" subjects_affected="142" subjects_at_risk="592"/>
                <counts group_id="E2" events="124" subjects_affected="70" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="114" subjects_affected="80" subjects_at_risk="592"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Physical examination procedures</sub_title>
                <counts group_id="E1" events="46" subjects_affected="33" subjects_at_risk="592"/>
                <counts group_id="E2" events="33" subjects_affected="20" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone related signs and symptoms</sub_title>
                <counts group_id="E1" events="59" subjects_affected="41" subjects_at_risk="592"/>
                <counts group_id="E2" events="44" subjects_affected="26" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Joint related signs and symptoms</sub_title>
                <counts group_id="E1" events="263" subjects_affected="134" subjects_at_risk="592"/>
                <counts group_id="E2" events="112" subjects_affected="67" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Muscle pains</sub_title>
                <counts group_id="E1" events="104" subjects_affected="59" subjects_at_risk="592"/>
                <counts group_id="E2" events="59" subjects_affected="35" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue pain and discomfort</sub_title>
                <counts group_id="E1" events="355" subjects_affected="171" subjects_at_risk="592"/>
                <counts group_id="E2" events="212" subjects_affected="79" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches NEC</sub_title>
                <counts group_id="E1" events="227" subjects_affected="83" subjects_at_risk="592"/>
                <counts group_id="E2" events="86" subjects_affected="38" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="63" subjects_affected="42" subjects_at_risk="592"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathies NEC</sub_title>
                <counts group_id="E1" events="57" subjects_affected="46" subjects_at_risk="592"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbances in initiating and maintaining sleep</sub_title>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="592"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder and urethral symptoms</sub_title>
                <counts group_id="E1" events="47" subjects_affected="38" subjects_at_risk="592"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing abnormalities</sub_title>
                <counts group_id="E1" events="59" subjects_affected="48" subjects_at_risk="592"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Coughing and associated symptoms</sub_title>
                <counts group_id="E1" events="51" subjects_affected="43" subjects_at_risk="592"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythemas</sub_title>
                <counts group_id="E1" events="76" subjects_affected="40" subjects_at_risk="592"/>
                <counts group_id="E2" events="37" subjects_affected="22" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Pruritus NEC</sub_title>
                <counts group_id="E1" events="50" subjects_affected="30" subjects_at_risk="592"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="294"/>
              </event>
              <event>
                <sub_title>Rashes, eruptions and exanthems NEC</sub_title>
                <counts group_id="E1" events="47" subjects_affected="33" subjects_at_risk="592"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disorders NEC</sub_title>
                <counts group_id="E1" events="62" subjects_affected="49" subjects_at_risk="592"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="294"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that result communications shall be exchanged and discussed with the sponsor 60 days prior to submission for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director</name_or_title>
      <organization>Menarini Ricerche SpA</organization>
      <email>abagovomab@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

